Story
Veradermics Stock Slides Amid Insider Selling and Widening Losses

Shares of Veradermics Inc. (MANE) declined 4.8% in mid-day trading to $97.90, pressured by a combination of significant insider stock sales, widening operating losses, and concerns over potential share dilution.
The stock's slide follows a cluster of recent disposals by company insiders, which has created a significant overhang for investors despite the sales being executed under pre-arranged plans.
Insider Sales Weigh on Sentiment
Recent filings with the U.S. Securities and Exchange Commission revealed several large transactions by key figures at Veradermics, signaling to the market that insiders are monetizing their holdings near recent highs. The most notable sales include:
- CEO Reid Alexander Waldman sold 67,500 shares on August 17, representing about 28% of his direct stake.
- Montanova Capital LLC, an entity affiliated with a director, sold 750,000 shares on August 19, a reduction of nearly 62% of its position.
- Director-linked entities associated with John W. Childs sold 100,000 shares on August 12.
While these sales were conducted under Rule 10b5-1 trading plans, the concentrated volume of selling from multiple insiders has suppressed investor confidence.
Financial Headwinds and Dilution Risk
AdAdding to the pressure, Veradermics reported a second-quarter net loss of $23.5 million, a significant increase from the $15.6 million loss reported in the same period a year prior. The company attributed the wider loss to increased spending on clinical and operational activities ahead of its upcoming Phase 2/3 study for VDPHL01, its oral treatment for female pattern hair loss.
Furthermore, the company registered an additional 16.77 million shares for potential sale in early August, raising concerns about near-term supply and the potential for dilution of existing shareholders' equity.
Market Context
The selling pressure on Veradermics occurred amid a slightly negative broader market, with the S&P 500 and NASDAQ both trading marginally lower. Although analysts at Citi and Jefferies maintain constructive ratings on the stock, their positive outlooks have not been sufficient to counteract the immediate headwinds from the insider liquidations and financial results.
The stock traded as low as $93.81 during the session, well below its 52-week high of $131.24, as investors weigh the company's long-term clinical prospects against the challenging short-term setup.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.